Drug intelligence / Profile preview

Happinose

Development stage: Unknown
Lead developer: Alcon
Modality: Small Molecules
Administration: Topical, Intranasal

Overview

Happinose is an over-the-counter (OTC) soothing nasal decongestant balm developed and marketed by Diomed Developments Ltd. The product contains levomenthol (0.3% w/w) as its active ingredient, formulated in a translucent, lubricating ointment base for topical application to the nasal passages. Its mechanism of action involves the stimulation of cold-sensitive sensory receptors in the nasal mucosa, which produces a cooling sensation that helps relieve symptoms of congestion associated with the common cold, catarrh, head colds, and hay fever. It is classified as a General Sales List (GSL) medicine in the United Kingdom.

Brand names: Happinose
Other names: Happinose Nasal Balm

Targets

TRPM8 (Transient receptor potential cation channel subfamily M member 8)

Beyond the preview

Go deeper on Happinose.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Happinose.

Explore the full profile